Last edition
News about "expanded Market Authorisation (MA)"
LYNKUET (Elinzanetant) Gets Expanded Canada Approval for Breast Cancer-Related Hot Flashes
LYNKUET (elinzanetant) receives expanded Canadian authorisation to treat moderate to severe hot flashes and night sweats caused by breast cancer Adjuvant Endocrine Therapy (AET).
Expanded Market Authorisation (MA) | 18/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members